Technology Listings

Polyclonal Antibodies Directed Against PHAPI/I1PP2A/PP32/LANP/etc. (E32+E36) and PHAPII/I2PP2A/SET/Nup214/TAF2beta/etc. (E38)

  • Immunoprecipitation
  • Immunofluorescence
  • Immunoblotting

Polyclonal antibodies that recognize PHAPs/IPP2As/etc. isoforms

Technical Summary

It has been reported that PHAPs/IPP2As/SET/etc. are increased or to have alterations in the expression of their different isoforms/alternative splice variants in a number of human tumors such as leukemias, Wilms tumor, and prostate cancer. The expression of these peptides may therefore provide useful clinical markers for cancer diagnosis and staging of tumors. Dr. Pallas has made several pan type antibodies that should recognize multiple isoforms of these proteins and allow for rapid detection of these proteins and their isoforms. Polyclonal antibodies have been made to two different PHAPI peptides and to one I2PP2A/SET peptide. Several residues were mixed to cover multiple species and isoforms. All of these antibodies can be used for Western blotting and recognize multiple species that probably correspond to multiple alternate splice variants of these proteins known to exist. E32 works in immunoprecipitation of denatured PHAP but only for species of 60-65 kDa and E38 can immunoprecipitate native and denatured PHAPII of the proper molecular size. E36 does not immunoprecipitate. All three of these antibodies have been tested in immunofluorescence and give nice nuclear immunofluorescence as would be expected for the reported localization of these proteins.

Patent Information
Tech ID: 01095
Published: 2/24/2009
Research Tools

Rajsekhar Guddneppanavar
Licensing Associate
Emory University

David Pallas